Alcon acquires Sirion products
Alcon is to buy the rights in the United States for two FDA-approved topical eye care products from Sirion Therapeutics, Inc Durezol, a marketed ophthalmic corticosteroid approved for the treatment of inflammation and pain associated with eye surgery, and Zirgan, a recently approved antiviral for the treatment of acute herpetic keratitis (corneal ulcers).
Alcon is to buy the rights in the United States for two FDA-approved topical eye care products from Sirion Therapeutics, Inc Durezol, a marketed ophthalmic corticosteroid approved for the treatment of inflammation and pain associated with eye surgery, and Zirgan, a recently approved antiviral for the treatment of acute herpetic keratitis (corneal ulcers).
The acquisition of these products from Sirion is part of our business development strategy to gain access to late-stage or approved products that will incrementally add to sales in the near-term, while also building our long-term pipeline, said Kevin Buehler, Alcon's president and chief executive officer. Upon closing, this deal will allow Alcon to capitalize on the US registration approval for Durezol and Zirgan with the existing commercial capability in the United States to maximize the brand development and revenue opportunities.
The agreement is expected to close by the end of the first quarter of 2010 and is contingent upon customary closing conditions and required regulatory approvals.
